To the full analysis
AngioDynamics stock: growth
ANGOAngioDynamics reported $320.17M in revenue for fiscal 2026, up 9.5% on the prior year, up 1.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.7%
per year from 2007 to 2026, per share 1.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
−5.4%
per year from 2007 to 2026, per share −9.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 1.9% | −1.0% | 5.7% |
| Revenue per share | 0.3% | −2.4% | 1.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −51.5% | −35.3% | −5.4% |
| Free cash flow per share | −52.3% | −36.2% | −9.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $112.23M | −$9.13M | $1.45M |
| 2008 | $166.5M | $10.89M | $19.2M |
| 2009 | $195.05M | $9.93M | −$1.5M |
| 2010 | $216.04M | $12.31M | $34.92M |
| 2011 | $215.96M | $8.12M | $30.8M |
| 2012 | $221.79M | −$5.18M | $8.56M |
| 2013 | $342.03M | −$1.21M | $13.73M |
| 2014 | $354.46M | $2.35M | $12.07M |
| 2015 | $356.97M | −$3.39M | $12.95M |
| 2016 | $353.69M | −$43.59M | $39.62M |
| 2017 | $349.64M | −$7.05M | $52.74M |
| 2018 | $344.29M | $16.34M | $37.63M |
| 2019 | $359.48M | $61.34M | $34.32M |
| 2020 | $264.16M | −$166.79M | −$22.14M |
| 2021 | $291.01M | −$31.55M | $18.91M |
| 2022 | $316.22M | −$26.55M | −$11.49M |
| 2023 | $338.75M | −$52.44M | −$4.27M |
| 2024 | $303.91M | −$184.35M | −$33.93M |
| 2025 | $292.5M | −$33.99M | −$14.59M |
| 2026 | $320.17M | −$36.74M | $508K |
Revenue by segment
How AngioDynamics, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Med Device$197.5M65%
- Med Tech$106.4M35%
The company split earlier years differently. A history would not be comparable, so only 2024 is shown.
Figures as a table
| 2024 | Share 2024 | |
|---|---|---|
| Med Device | $197.51M | 65% |
| Med Tech | $106.4M | 35% |
| Total revenue | $303.91M | 100% |
Revenue by region
Where AngioDynamics, Inc. generates its revenue.
- United States$274.9M86%
- Outside the US$45.3M14%
The company split earlier years differently. A history would not be comparable, so only 2026 is shown.
Figures as a table
| 2026 | Share 2026 | |
|---|---|---|
| United States | $274.92M | 85.9% |
| Outside the US | $45.25M | 14.1% |
| Total revenue | $320.17M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 May 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.